Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis
NCT ID: NCT02897817
Last Updated: 2018-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
471 participants
OBSERVATIONAL
2016-06-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Methotrexate Adherence in Rheumatoid Arthritis Patients
NCT05535686
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
NCT02553018
Methotrexate Use Improvement in Rheumatoid Arthritis Using Biomarker Feedback
NCT03913728
Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis
NCT02288520
A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
NCT00299104
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral to Injectable
Patients treated with oral MTX and requiring a switch to injectable MTX
No interventions assigned to this group
Injectable to Injectable
Patients treated with injectable MTX and eligible for a change in MTX injection device.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of RA as confirmed by the ACR/EULAR (2010) Classification Criteria for Rheumatoid Arthritis
* Patients:
* currently treated with oral MTX and requiring a switch to an injectable MTX\* or
* currently treated with an injectable MTX\* and eligible for a change of MTX injection device\*
* Patients informed about and accepting the computer processing of their medical data and their right of accesss and correction.
Exclusion Criteria
\*On the basis of the products marketed at the time of submission of the study to Oversight Authorities (Méthotrexate Biodim®, Metoject® and imeth®).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nordic Pharma SAS
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
René-Marc FLIPO, MD, Prof
Role: PRINCIPAL_INVESTIGATOR
CHU Hôpital Roger Salengro, LILLE
Eric SENBEL, MD
Role: PRINCIPAL_INVESTIGATOR
Doctor's Office, MARSEILLE
Sonia TROPE, Nurse
Role: PRINCIPAL_INVESTIGATOR
ANDAR
Hélène HERMAN-DEMARS, MD
Role: STUDY_DIRECTOR
NORDIC PHARMA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nordic Pharma
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APRim
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.